What gene mutations do you always test for prior to starting EGFR inhibitor therapy in metastatic colon cancer?
Would you advocate for a targeted gene approach or a fully comprehensive NGS panel?
Answer from: Medical Oncologist at Academic Institution
Molecular testing for delivery of personalized treatment should be done at the time of diagnosis in patients with metastatic disease. While RAS-wild type is a requirement for EGFR-AB, the presence of BRAF (V-600E) mutation and HRE2 amplification confer resistance to EGFR-AB.
I recommend testing for...
Comments
Medical Oncologist at Mayo Clinic Agree with Dr. @Barzi's comments. I would add that...
Answer from: Medical Oncologist at Academic Institution
At a minimum, I operate with pan-RAS, BRAF (yes, even for left sided tumors), MMR/MSI, RNA fusion/rearrangement, and HER2 testing prior to anti-EGFR therapy. Obviously, you would not want to give an EGFR inhibitor to a RAS mutated cancer, but similarly, I need to know the BRAF (particularly V600E) u...
Agree with Dr. @Barzi's comments. I would add that...